Another encouraging quote from the Warma interview"If this study demonstrates proof-of-concept for our lead product in Alzheimer's, it unlocks the value of the entire pipeline. Given today’s valuation, we strongly believe there is a significant disconnect between our current valuation and the potential of this company. If we can unlock some of this potential in the coming months, I think investors, pharma companies, and, most importantly, patients will start to realize the value ProMIS is creating as a promising treatment for multiple dementias and neurodegenerative diseases."